Study demonstrates consistent, durable outcomes at six and 12 months with very low incidence of GvHD
HOUSTON, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the presentation of updated clinical results from its multicenter BP-004 clinical trial of BPX-501 and rimiducid at the 2017 BMT Tandem Meetings. Results on 73 patients with more than six months of follow-up demonstrated that the use of BPX-501 following an alpha/beta-depleted, haploidentical hematopoietic stem cell transplant (haplo-HSCT) resulted in rapid immune recovery in patients with inherited blood disorders and hematological cancers.
“The results from our BPX-501 clinical program continue to demonstrate positive and consistent results across multiple centers and diseases, underscoring its potential to address the needs of a wide range of pediatric patients who lack access to a suitable matched donor,” commented Rick Fair, President and CEO of Bellicum Pharmaceuticals. “The data reported today, including incidences of GvHD- and disease-free outcomes in children with blood cancers and genetic diseases, compare favorably to historical outcomes in patients receiving a matched unrelated donor (MUD) transplant, the comparative population for our ongoing registration trial in Europe.”
Updated Results of BP-004 Study
To date, 122 pediatric patients have undergone treatment with BPX-501. Investigators reported on 91 patients with 100 days of follow-up, 73 patients with six months, and 45 patients with more than one year of follow-up. Genetic blood diseases (n=54) include SCID (Severe Combined Immune Deficiency) (n=11), thalassemia major (n=8), Wiskott-Aldrich syndrome (n=6), sickle cell disease (n=3), and several others. Hematological cancers (n=37) include ALL (acute lymphoblastic leukemia) (n=22), AML (acute myeloid leukemia) (n=13), and others.
Patients receiving BPX-501 following a haplo-HSCT demonstrated rapid immune reconstitution by month six, including full recovery and normalization of T-cells, B-cells and immunoglobulins. Cumulative incidence of treatment-related mortality remains very low in the BP-004 study, with six-month and one-year survival rates of 98.4 percent and 97.2 percent, respectively, and no mortality associated with use of BPX-501 or rimiducid. Of 73 patients with more than six months of follow-up, 22 percent had acute Grade 1-2 GvHD, 2.7 percent had Grade 3, and there were no cases of Grade 4 GvHD. In the BP-004 study, rimiducid was used on six patients experiencing GvHD that was not controlled by the use of standard treatments. In all five cases of uncontrolled acute GvHD, the administration of rimiducid rapidly resolved the symptoms. As previously reported, there was one case of severe chronic GvHD attributed to cells from the donor graft, and unrelated to BPX-501, in a malignant patient that did not resolve with administration of rimiducid.
The poster presentation can be accessed in the Events and Presentations section of the Bellicum website.
BPX-501 is an adjunct T-cell therapy administered after allogeneic HSCT, comprising genetically modified donor T cells incorporating Bellicum’s CaspaCIDe® safety switch. It is designed to provide a safety net to eliminate alloreactive BPX-501 T cells (via administration of activator agent rimiducid) should uncontrollable GvHD occur. This enables physicians to more safely perform stem cell transplants by adding back BPX-501 engineered T cells to speed immune reconstitution and provide control over viral infections, without unacceptable GvHD risk. The ongoing BP-004 clinical study of BPX-501 is being conducted at transplant centers in the U.S. and Europe.
About the BMT Tandem Meetings
The BMT Tandem Meetings are the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT). Attended by investigators, clinicians, laboratory technicians, clinical research professionals, nurses, pharmacists, administrators, and allied health professional attendees, the scientific program addresses the most timely issues in hematopoietic cell transplantation.
About Bellicum Pharmaceuticals
Bellicum is a leader in developing novel, controllable cellular immunotherapies for cancers and for orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bellicum may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," “designed,” "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research and development activities relating to BPX-501, rimiducid and CaspaCIDe; the effectiveness of rimiducid and of CaspaCIDe; the effectiveness of BPX-501 and its possible range of application and potential curative effects and safety in the treatment of diseases including as compared to other treatment options and competitive therapies; the timing and success of our BP-004 clinical trial, including the rate and progress of enrollment; and, the timing of regulatory filings for BPX-501 and for rimiducid. Various factors may cause differences between Bellicum’s expectations and actual results as discussed in greater detail under the heading “Risk Factors” in Bellicum’s filings with the Securities and Exchange Commission, including without limitation our annual report on Form 10-K for the year ended December 31, 2015. Any forward-looking statements that Bellicum makes in this press release speak only as of the date of this press release. Bellicum assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Bellicum PharmaceuticalsAlan Musso, CFO
BMC CommunicationsBrad Miles, 646-513-3125